Policy & Recommendations
News
Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA
ECDC, together with the EU/EEA Member States and the European Commission has increased its monitoring activities and will revise risk assessments and adjust actions if needed.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
What COVID-19 Vaccines Can and Cannot Do: Setting Realistic Goals in the Current Pandemic
The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication.
News
Partner Organisations
The biggest diabetes research stories of 2022
2022 has been a big year for diabetes research, filled with historic moments and world-firsts. Here we take a look back at some of the incredible progress Diabetes UK-funded scientists and diabetes researchers across the globe have been behind this year.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.
Risk of Type 1 Diabetes in Children is Not Increased after SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark
It has been hypothesized that SARS-CoV-2 infection in children can increase risk of developing type 1 diabetes.
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
RSV infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection.
The cost of health care: how to make it affordable
Watch Robert Yates, political health economist specialising in Universal Health Coverage (UHC) at Chatham House, discuss with The Economist on the International UHC Day.
Life-course immunization: Country landscape report
This project was commissioned to collect evidence focused on specific life-course approach to immunization (LCI) policies and priority geographies, and to compare available data sets and case studies before and during the COVID-19 pandemic.
News
Policy & Recommendations
Council calls for combatting vaccine hesitancy and closer EU cooperation
EU Ministers of Health approved Council conclusions on vaccination as one of the most effective tools for preventing disease and improving public health.
News
Policy & Recommendations
COVI Committee at the European Parliament evaluates the socio-economic impact of the COVID-19 pandemic on children
Members of the European Parliament looked at the possible consequences to children's well-being, including their mental health.
